Skip to Main Content

Paper Details

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
J Clin Oncol
68
2021
BC, HER2, HER2+, HER2+ BC, HER2-Positive Breast Cancer, Paclitaxel, Patients, T, T-DM1, Trastuzumab, Trastuzumab Emtansine, alopecia, human, human epidermal growth factor receptor 2, human epidermal growth factor receptor 2-positive (HER2+) breast cancer, neuropathy, paclitaxel, patient, patients, trastuzumab, trastuzumab emtansine
Author NameAffiliation
Sara M TolaneyDana-Farber Cancer Institute
Sara M TolaneyHarvard Medical School
Steven J IsakoffMassachusetts General Hospital
Ron BoseWashington University
Antonio C WolffJohns Hopkins Sidney Kimmel Cancer Center
Paul K MarcomDuke University
Blair ArdmanLowell General Hospital
Rita NandaThe University of Chicago
Mothaffar F RimawiDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Minetta C LiuMayo Clinic
Kathryn J RuddyMayo Clinic
Eric P WinerDana-Farber Cancer Institute
Eric P WinerHarvard Medical School
Ian E KropDana-Farber Cancer Institute
Ian E KropHarvard Medical School
  • 1 - 15

Datasets

Release 1.2